Literature DB >> 14576155

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.

Joseph F Gera1, Ingo K Mellinghoff, Yijiang Shi, Matthew B Rettig, Chris Tran, Jung-hsin Hsu, Charles L Sawyers, Alan K Lichtenstein.   

Abstract

Prior work demonstrates that AKT activity regulates sensitivity of cells to G(1) arrest induced by mammalian target of rapamycin (mTOR) inhibitors such as rapamycin and CCI-779. To investigate this, a novel high-throughput microarray polysome analysis was performed to identify genes whose mRNA translational efficiency was differentially affected following mTOR inhibition. The analysis also allowed the assessment of steady-state transcript levels. We identified two transcripts, cyclin D1 and c-myc, which exhibited differential expression in an AKT-dependent manner: High levels of activated AKT resulted in rapamycin-induced down-regulation of expression, whereas low levels resulted in up-regulation of expression. To ectopically express these proteins we exploited the finding that the p27(kip1) mRNA was efficiently translated in the face of mTOR inhibition irrespective of AKT activity. Thus, the p27(kip1) 5'-untranslated region was fused to the cyclin D1 and c-myc coding regions and these constructs were expressed in cells. In transfected cells, expression of cyclin D1 or c-myc was not decreased by rapamycin. Most importantly, this completely converted sensitive cells to a phenotype resistant to G(1) arrest. Furthermore, the AKT-dependent differential expression patterns of these two genes was also observed in a mouse xenograft model following in vivo treatment with CCI-779. These results identify two critical downstream molecular targets whose expression is regulated by AKT activity and whose down-regulation is required for rapamycin/CCI-779 sensitivity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576155     DOI: 10.1074/jbc.M309999200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  140 in total

1.  MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells.

Authors:  Y Shi; P Frost; B Hoang; Y Yang; R Fukunaga; J Gera; A Lichtenstein
Journal:  Oncogene       Date:  2012-02-27       Impact factor: 9.867

2.  Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer.

Authors:  Guang Chen; Na Yang; Xiang Wang; Si-Yuan Zheng; Yi Chen; Lin-Jiang Tong; Yi-Xue Li; Ling-Hua Meng; Jian Ding
Journal:  J Mol Med (Berl)       Date:  2010-05-28       Impact factor: 4.599

3.  A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.

Authors:  Andrew J Armstrong; George J Netto; Michelle A Rudek; Susan Halabi; David P Wood; Patricia A Creel; Kelly Mundy; S Lindsay Davis; Ting Wang; Roula Albadine; Luciana Schultz; Alan W Partin; Antonio Jimeno; Helen Fedor; Phillip G Febbo; Daniel J George; Robin Gurganus; Angelo M De Marzo; Michael A Carducci
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

Review 4.  Signaling by target of rapamycin proteins in cell growth control.

Authors:  Ken Inoki; Hongjiao Ouyang; Yong Li; Kun-Liang Guan
Journal:  Microbiol Mol Biol Rev       Date:  2005-03       Impact factor: 11.056

5.  IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1.

Authors:  Yijiang Shi; Patrick J Frost; Bao Q Hoang; Angelica Benavides; Sanjai Sharma; Joseph F Gera; Alan K Lichtenstein
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

6.  A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.

Authors:  Julie E Bauman; Hugo Arias-Pulido; Sang-Joon Lee; M Houman Fekrazad; Hiroyuki Ozawa; Elana Fertig; Jason Howard; Justin Bishop; Hao Wang; Garth T Olson; Michael J Spafford; Dennie V Jones; Christine H Chung
Journal:  Oral Oncol       Date:  2013-02-04       Impact factor: 5.337

7.  Chemoproteomic Profiling Uncovers CDK4-Mediated Phosphorylation of the Translational Suppressor 4E-BP1.

Authors:  Dylan C Mitchell; Arya Menon; Amanda L Garner
Journal:  Cell Chem Biol       Date:  2019-05-02       Impact factor: 8.116

8.  mTOR signaling and transcriptional regulation in T lymphocytes.

Authors:  Hu Zeng; Hongbo Chi
Journal:  Transcription       Date:  2014

Review 9.  Common corruption of the mTOR signaling network in human tumors.

Authors:  S Menon; B D Manning
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

10.  Montelukast enhances cytocidal effects of carfilzomib in multiple myeloma by inhibiting mTOR pathway.

Authors:  Jia Tong; Qing Yu; Wenbin Xu; Wenjun Yu; Chao Wu; Yingli Wu; Hua Yan
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.